SHP-2 Phosphatase Prevents Colonic Inflammation by Controlling Secretory Cell Differentiation and Maintaining Host-Microbiota Homeostasis

GENEVIEVE COULOMBE,1 ARIANE LANGLOIS,1 GIADA DE PALMA,2 MARIE-JOSÉE LANGLOIS,1 JUSTIN L. MCCARVILLE,2 JESSICA GAGNÉ-SANFAÇON,1 NATHALIE PERREAULT,1 GEN-SHENG FENG,3 PREMYSL BERCÍK,2 FRANÇOIS BOUDREAU,1 ELENA F. VERDU,2 AND NATHALIE RIVARD1*

1Faculty of Medicine and Health Sciences, Department of Anatomy and Cell Biology, Cancer Research Pavilion, Université de Sherbrooke, Sherbrooke, Quebec, Canada
2Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada
3Department of Pathology and Division of Biological Sciences, University of California San Diego, La Jolla, California

Polymorphisms in the PTPN11 gene encoding for the tyrosine phosphatase SHP-2 were described in patients with ulcerative colitis. We have recently demonstrated that mice with an intestinal epithelial cell-specific deletion of SHP-2 (SHP-2IEC-KO) develop severe colitis 1 month after birth. However, the mechanisms by which SHP-2 deletion induces colonic inflammation remain to be elucidated. We generated SHP-2IEC-KO mice lacking Myd88 exclusively in the intestinal epithelium. The colonic phenotype was histologically analyzed and cell differentiation was determined by electron microscopy and lysozyme or Alcian blue staining. Microbiota composition was analyzed by 16S sequencing. Results show that innate defense genes including those specific to Paneth cells were strongly up-regulated in SHP-2-deficient colons. Expansion of intermediate cells (common progenitors of the Goblet and Paneth cell lineages) was found in the colon of SHP-2IEC-KO mice whereas Goblet cell number was clearly diminished. These alterations in Goblet/intermediate cell ratio were noticed 2 weeks after birth, before the onset of inflammation and were associated with significant alterations in microbiota composition. Indeed, an increase in Enterobacteriaceae and a decrease in Firmicutes were observed in the colon of these mice, indicating that dysbiosis also occurred prior to inflammation. Importantly, loss of epithelial Myd88 expression inhibited colitis development in SHP-2IEC-KO mice, rescued Goblet/intermediate cell ratio, and prevented NFκB hyperactivation and inflammation. These data indicate that SHP-2 is functionally important for the maintenance of appropriate barrier function and host-microbiota homeostasis in the large intestine.

J. Cell. Physiol. 231: 2529–2540, 2016. © 2016 The Authors. Journal of Cellular Physiology published by Wiley Periodicals, Inc.

Crohn’s disease (CD) and ulcerative colitis (UC) are multifactorial inflammatory bowel diseases, involving various interactions among genetic, luminal, and environmental factors that lead to dysregulated inflammation (Kaser et al., 2010). Recent genome-wide association studies have highlighted the important contribution of genetic susceptibility in development of these diseases. These studies have identified 163 independent loci for IBD including 110 loci linked to both CD and UC. This suggests common pathways in CD and UC pathogenesis, although differences in clinical phenotypes remain (Cho and Brant, 2011; Coskun, 2014). Thirty gene loci have been classified as CD specific and 23 as UC specific. CD is associated with abnormal intracellular processing of bacteria, autophagy, and innate immunity, whereas UC is associated with epithelial barrier dysfunction.

Recently, tyrosine phosphatase (PTP) variants in the PTPN22, PTPN2, and PTPN11 genes were associated with IBD onset (Spalinger et al., 2015). In particular, intronic polymorphisms in the PTPN11 gene encoding for the tyrosine phosphatase SHP-2 were described in Japanese patients with UC (Narumi et al., 2009). However, the impact of these polymorphisms on SHP-2 function was not elucidated. The authors speculated that PTPN11 polymorphisms may change the expression, activity, or binding of SHP-2 to receptors in T and B cells. However, this phosphatase is not only expressed in immune cells but also in intestinal epithelial cells (IECs).

Importantly, IECs are critical in the maintenance of immune homeostasis in the intestine. Indeed, they form a chemical and physical barrier separating luminal microbes and immune cells, and participate in local inflammation response following a mucosal insult (Peterson and Artis, 2014). We thus recently

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Contract grant sponsor: Canadian Institutes of Health Research; Contract grant number: MOP-142336.

*Correspondence to: Nathalie Rivard, Faculty of Medicine and Health Sciences, Department of Anatomy and Cell Biology, Cancer Research Pavilion, Université de Sherbrooke, 3201, Jean Mignault, Sherbrooke, QC, Canada J1E4K8. E-mail: nathalie.rivard@usherbrooke.ca

Manuscript Received: 11 March 2016 Manuscript Accepted: 19 April 2016 Accepted manuscript online in Wiley Online Library (wileyonlinelibrary.com): 21 April 2016 DOI: 10.1002/jcp.25407
analyzed the role of SHP-2 in this tissue by generating mice with an IEC-specific deletion of SHP-2 expression. These mice rapidly develop inflammation 1 month after birth, with histopathological features typical of UC (Coulombe et al., 2013). Of note, inflammation was not detected in the small intestine. Additionally, we found reduced SHP-2 expression in intestinal biopsies from patients with active UC, emphasizing the inverse correlation between SHP-2 levels and colonic inflammation (Coulombe et al., 2013). However, the exact molecular mechanisms by which SHP-2 epithelial deletion induces chronic inflammation in the colon remain to be elucidated.

Our objective in this study was to further characterize the mechanisms by which SHP-2 epithelial deletion induces chronic colonic inflammation in mice. We observed that 2 weeks after birth, SHP-2IEC-KO neonates feature reduced Goblet cell numbers associated with increased expression of several antimicrobial peptides (α-defensins, Reg3γ, Reg3β, and lysozyme) as well as expansion of Paneth cells in their small intestine and of intermediate cells in the colon. Microbiota composition was changed in SHP-2IEC-KO mice. Specifically, an increase in Enterobacteriaceae and a reduction in Firmicutes were observed in mutant mice, indicating that dysbiosis develops before the appearance of inflammation. Interestingly, epithelial Myd88 deletion inhibits colitis development and secretory cell fate alterations in SHP-2-deficient mice. Our results suggest that dysfunction in SHP-2 signaling severely impairs colonic epithelial barrier function resulting in microbiota-driven inflammation as observed in patients with IBD (Swidsinski et al., 2005; Fava and Danese, 2011). Hence, epithelial SHP-2 is a genetic factor that influences secretory cell fate, microbiota composition and therefore, intestinal homeostasis.

Materials and Methods

Animals

Shp-2fl/fllox/lox mice (F3) were backcrossed with C57BL/6 mice for nine generations. All experiments were performed with F12 mice. Myd88−/−/fl mice were purchased from The Jackson Laboratory (Bar Harbor, MA). The C57BL/6 12.4KbVilCre transgenic line was provided by Dr. Deborah Gumucio (University of Michigan, Ann Arbor, MI) (Madison et al., 2002). Mutations were genotyped according to manufacturer’s instructions or the published protocols (Madison et al., 2002). All experiments were approved by the Animal Research Ethics Committee of the Université de Sherbrooke.

Microarray analysis

RNA was isolated from total colon extracts of three controls and three SHP-2IEC-KO newborn mice using the RNeasy mini kit (Qiagen, Toronto, ON, Canada). RNA were sent to the McGill University and Génome Québec Innovation Centre and a GeneChip Mouse Genome 430 2.0 Array (Affymetrix, Cleveland, OH) was performed. Data analysis, normalization, average difference, and expression for each feature on the chip were performed using Flexarray 1.6.1 with default parameters (Microarray platform, McGill University and Genome Quebec Innovation Centre).

RNA isolation and quantitative PCR

RNA was isolated from total colon extracts in newborn mice or from scraped colonic mucosa in 2-week-old mice using the RNeasy mini kit (Qiagen). Reverse transcription were performed using AMV-RT (Roche Diagnostics, Laval, QC, Canada) according to the manufacturer’s instructions and qPCR were performed by the RNAomics Platform at the Université de Sherbrooke (QC, Canada).

Target expression was quantified relatively to Pum1, Sdha, and Tnsh4. Primer sequences and conditions are available upon request.

Histological staining and immunohistochemistry

Murine tissues were fixed in 4% paraformaldehyde overnight at 4°C, then dehydrated and embedded in paraffin. Sections of 5 μm were applied to Probe-On Plus slides (Fisher Scientific Canada, Nepean, ON, Canada) and kept at room temperature. Tissue preparation, embedding, and hematoxylin and eosin (H&E) coloration were described previously (Langlois et al., 2009) and were performed by the Electron Microscopy & Histology platform at the Université de Sherbrooke. For Paneth/Goblet staining, immunohistochemistry against lysozyme (Dako, Copenhagen, Danemark) was performed followed by an Alicant blue staining.

Electron microscopy

Tissues intended for electron microscopy analysis were fixed with 2.8% glutaraldehyde in 0.1 M cacaodylate buffer and processed as previously described (Boudreau et al., 2007).

Gut microbiota analysis

Bacterial DNA from the cecal content of mice was extracted through mechanical lysis by bead beating (BioSpec, Bartlesville, OK), followed by enzymatic-lysis and phenol:chloroform extraction. qPCR was used to quantify the different bacterial groups of the cecal microbiota using genus- and group-specific primers as described (Matsuki et al., 2002; Malinen et al., 2003). Briefly, PCR amplification and detection were performed with iCycler IQ5 detection system using SsoFastTM Evagreen supermix (Bio-Rad, Hercules, CA). The results are expressed as means ± SD of cycle threshold values (Ct). Ct values indicate the number of cycles required for the fluorescent signal to cross the threshold and are inversely proportional to the amount of target nucleic acid in the sample.

Deep sequencing analysis of 16S rRNA with Illumina

The V3 region of the 16S rRNA gene was amplified as described with modifications (Whelan et al., 2014). Products were separated from primers and primer dimers by electrophoresis on a 2% agarose gel. PCR products of the correct size were recovered using a QIAquick gel extraction kit (Qiagen). A total of 13,728,024 reads before quality filtering (an average of 292,085.617 reads per sample with a range of 120,066–401,952), 4,281,616 reads after quality filtering (an average of 84,652 reads per sample with a range of 516–147,427), and 10,219 OTUs (an average of 211.5 OTUs per sample, after quality filtering) were obtained from the 45 samples sequenced (6 control and 6 SHP-2IEC-KO mice aged of 4 days; 9 control and 7 SHP-2IEC-KO mice aged of 2 weeks; 8 control and 7 SHP-2IEC-KO mice aged of 1 month). Custom, in-house Perl scripts were developed to process the sequences after Illumina sequencing (Whelan et al., 2014). Cutadapt (Martin, 2011) was used to trim any over-read, and paired-end sequences were aligned with PANDAseq (Masella et al., 2012) with a 0.7 quality threshold. If a mismatch in the assembly of a specific set of paired-end sequences was discovered, they were culled. Additionally, any sequences with ambiguous base calls were also discarded.

Operational taxonomic units (OTUs) were picked using AbundantOTU-1 (Ye, 2011), and sequences were clustered to 97% sequence identity operational taxonomic units (OTUs). Taxonomy was assigned at a 0.8 threshold using the Ribosomal Database Project (RDP) (Caporaso et al., 2010) classifier v.2.2 trained against the Greengenes SSU database (February, 2011 release). For all downstream analyses, we filtered the obtained OTU table excluding ‘Root’ and excluding any sequence that was not present at least three times across the entire dataset.
Calculations of within-community diversity (α-diversity) and between-community diversity (β-diversity) were run using QIIME (Caporaso et al., 2010), and the phyloseq package (version 1.8.2) implemented in R (version 3.1.0) (McMurdie and Holmes, 2013). Alpha diversity index (Shannon) and richness (observed species) of each category were computed using the script compare_alpha_diversity.py in QIIME. The distance matrix calculated with Bray Curtis method on normalized data (all samples were subsampled to the same depth) was analyzed with PERMANOVA analysis using the script compare_categories.py in QIIME in order to assess the strength and statistical significance of sample groupings. Statistical analyses on the taxonomic composition of the colonic samples were done with the script group_significance.py in QIIME, which determines with Kruskal–Wallis test whether OTU relative abundance is different between categories. Before running the script, the OTU table was filtered, removing OTUs not present in at least 25% of samples. The P values obtained from the comparison between categories were then corrected with the “False discovery rate” (FDR) method. Secondly, we analyzed the taxonomic composition of the samples with multiple t-tests on the table L6 (the highest assigned taxonomic level) generated by running the script: summarize_taxa_through_plots.py in QIIME. The P values obtained from the comparison between groups were corrected with the Holm–Sidak method, with α = 5.000%.

Disease activity index (DAI)

SHP-2IEC-KO mice and control littermates were scored based on a scale from 0 to 4 for rectal bleeding, stool consistency, blood loss, and colonic hardness. Then, a cumulative DAI was calculated as previously detailed (Cooper et al., 1993).

Histological scoring

Cumulative histological scores were calculated as described (McCafferty et al., 1999) with a maximum possible score of 11. Briefly, features were graded as follows: extent of destruction of mucosal architecture (0, 1, 2, and 3, normal, mild, moderate, and extensive damage, respectively), presence, and degree of cellular infiltration (0, 1, 2, and 3, normal, mild, moderate, and transmural infiltration, respectively), extent of muscle thickening (0, 1, 2, and 3, normal, mild, moderate, and extensive thickening, respectively), presence or absence of Goblet cell depletion (0, absent; 1, present), and the presence or absence of crypt abscesses (0, absent; 1, present).

Western blot analysis

Proteins were isolated from scraped mucosa (1-month-old mice) in RIPA buffer and Western blots were performed as done before (Langlois et al., 2009). Antibodies against phosphorylated RelA (S536) (Cell Signaling, Danvers, MA) and β-actin (Millipore, Billerica, MA) were used for Western blot analyses. Horseradish peroxidase-anti-mouse and anti-rabbit antibodies were purchased from Amersham Biosciences (Pittsburg, PA).

**Statistical analysis**

Statistical analyses were calculated with GraphPad Prism 5 software (Irvine, CA). Student’s two-tailed t-test was used if a normal distribution could be assumed. Mann–Whitney U-test was performed elsewhere. Differences were considered significant at *P* ≤ 0.05, **P** ≤ 0.01, or ***P** ≤ 0.001.

**Results**

**Colonic expression of antimicrobial factors including Paneth cell markers in SHP-2IEC-KO neonates**

We have previously reported that SHP-2 ablation in the intestinal epithelium (SHP-2IEC-KO mice) does not compromise intestinal morphogenesis as observed by neonatal body weight, intestinal tissue architecture and cell differentiation (Coulombe et al., 2013). However, 1 month after birth, SHP-2IEC-KO mice spontaneously develop severe colitis which resembles to UC (Coulombe et al., 2013; Heuberger et al., 2014; Yamashita et al., 2014).

To identify the early genes altered by the loss of SHP-2 in colonic crypts, gene expression profiling was performed three days after birth. Data were analyzed by the Database for Annotation, Visualization, and Integrated Discovery (DAVID) software to generate protein networks under SHP-2 regulation. Intriguingly, some defense response genes including Defa (α-defensins), Ido-1, Leap-2, and Reg3β emerge as the highest up-regulated genes induced in SHP-2-deficient colons (Table I). To confirm the expression of antimicrobial genes, we performed several qPCR analyses instead of Western blots because many of these genes encode peptides that require proteolytic processing before secretion and activation and therefore, they are not easy to detect by Western blotting. Defensin group, for example, contains numerous diverse peptides and therefore we used primers to amplify the α-defensin subtype. As shown in Figure 1A, qPCR analyses confirmed the significant induction of antimicrobial genes including Defa (9.9-fold), Lyz1 (lysosome 1) (1.7-fold), and Reg3β (2.7-fold) three days after birth in the colon of SHP-2IEC-KO neonates (Fig. 1A). In addition, increased expression of matrix metalloproteinase-7 (Mmp7), an enzyme that cleaves the inactive precursors pro-α-defensins into active α-defensins was also observed (Fig. 1A). Of note, 2 weeks after birth, the increase in the expression of these genes was even more pronounced: Defa by 5,865-fold, Lyz1

| Table I. Up-regulated genes induced in SHP-2IEC-KO colons (n = 3 mice per group) |
|-----------------|-----------------|-----------------|-----------------|
| Gene            | Identification  | Relative expression | P               |
| Defensin. alpha 24 (Defa24) | 1450631_x_at     | 4.15             | 2.80 × 10^-6    |
| Indoleamine 2.3-dioxynegase 1 (Idd1) | 1420437_at     | 2.80             | 0.014           |
| Inteleukin 1 receptor-like 1 (Il1r1) | 1422317_a_at     | 2.57             | 0.021           |
| Chemokine (C-X-C motif) ligand 5 (Cxc5) | 1419728_at     | 2.39             | 0.047           |
| Liver-expressed antimicrobial peptide 2 (Leap2) | 1427480_at     | 2.34             | 2.75 × 10^-4    |
| Regenerating islet-derived 3 beta (Reg3β) | 1416297_s_at     | 2.12             | 3.50 × 10^-5    |
| Leukocyte cell-derived chemotaxin 2 (Lect2) | 1449492_at     | 2.04             | 9.81 × 10^-5    |
| Chemokine (C-C motif) ligand 20 (Ccl20) | 1422029_at     | 1.93             | 3.51 × 10^-3    |
| Complement component 2 (C2) | 1416051_at     | 1.65             | 9.99 × 10^-5    |
| Chemokine (C-C motif) ligand 25 (Ccl25) | 1418777_at     | 1.65             | 3.10 × 10^-4    |
| Regenerating islet-derived 3 gamma (Reg3γ) | 1448872_at     | 1.63             | 0.014           |
| Alpha-2-HS- glycoprotein (Ahsg) | 1455093_a_at     | 1.58             | 0.041           |
| Inteleukin 18 receptor 1 (Il1r1) | 1421628_at     | 1.55             | 1.77 × 10^-3    |
| Radical S- adenosyl methionine domain containing 2 (Rsd2) | 1436058_at     | 1.54             | 0.025           |
| Interferon regulatory factor 7 (Irf7) | 1417244_a_at     | 1.51             | 7.75 × 10^-4    |
by 140-fold, Reg3β by 39-fold, Reg3γ by 81-fold, and Mmp7 by 32-fold (Fig. 1B). Increased expression of these antimicrobial factors was also found in the small intestine of newborn and 2-week-old SHP-2IEC-KO mice (Fig. S1A and B, Supporting Information).

The increased expression of Defa and Lyz1 in the colon of SHP-2-deficient mice was surprising as in mice, the production of these mRNAs normally occurs in Paneth cells exclusively located in the small intestine (Bevins and Salzman, 2011). We thus decided to verify the putative presence of Paneth-like cells in the colon of our mutant mice by using lysozyme staining and/or H&E coloration revealing cytoplasmic eosinophilic granules of these cells. As expected, in control mice, Paneth cells were restricted at the base of the small intestinal crypts (Fig. S2, see arrows, Supporting Information) and these cells were absent from colonic crypts (Fig. 2A and B). By contrast, 2 weeks after birth, SHP-2IEC-KO mice exhibited cells with eosinophilic granules and lysozyme staining not only in the small intestine (Fig. S2, see arrows and data not shown, Supporting Information) but also in the colon (Fig. 2A and B, see arrows).
Thus, Paneth cell specific genes and Paneth-like cells were observed in the colonic crypt of mutant mice, respectively, 3 days and 2 weeks after birth and then, before the appearance of histopathological manifestations of inflammation (Coulombe et al., 2013). Concomitantly, reduced mucin staining and Goblet cell number were observed in colons of 2-week-old and 1-month-old SHP-2IEC-KO mice (Fig. 2C), as we previously reported (Coulombe et al., 2013).

Expansion of intermediate cells in the colon of SHP-2IEC-KO mice

The phenotype of lysozyme-positive cells observed in the colon tissue from SHP-2IEC-KO mice was further analyzed by electron microscopy. Interestingly, as shown in Figure 3A, colonic lysozyme-positive cells of SHP-2IEC-KO mice exhibited a different morphology compared to typical small intestinal...
Paneth cells. Indeed, Paneth-like cell granules in SHP-2-deficient colons were strikingly different, with the granules being irregular in size, less dense with a lattice-like appearance at periphery (Fig. 3A, see arrows). This phenotype was reminiscent to the phenotype of intermediate cells which were previously found in the small intestine, at the junctions of the crypt-villus axis (Calvert et al., 1988). These cells presumably represent the common precursors of the Paneth and Goblet cell lineages in the small intestine (Kamal et al., 2001), expressing both Paneth cell and Goblet cell markers. Accordingly, co-staining for lysozyme and Alcian blue in control small intestines confirmed that dual-positive cells were rare and that Alcian blue-positive cells were distinct from lysozyme-positive cells (King et al., 2013) (Fig. 3B). In contrast, in the colon of SHP-2IEC-KO mice, we easily detected the presence of both lysozyme-negative/Alcian blue-positive cells and also lysozyme-positive/Alcian blue-positive cells within the crypts (Fig. 3C, see arrows). Thus, these data suggest that the expansion of the lysozyme-positive cells in the colon of SHP-2IEC-KO mice is due to an increased number of intermediate cells that exhibit some characteristics typical of both Goblet and Paneth cells. These data suggest that SHP-2-dependent signaling directs Goblet cell differentiation in the colon following progenitor specification.

Loss of IEC-specific SHP-2 affects microbiota composition

Antimicrobial peptides including defensins not only protect the intestinal mucosa against pathogens but also shape the composition of the resident microbiota (Salzman et al., 2010). We thus evaluated whether loss of SHP-2 in IECs led to
intestinal microbiota changes. We observed that neonatal control and SHP-2IEC-KO mice had similar gut microbiota composition (Fig. 4A). However, at 2 weeks of age, we observed significant changes in the microbiota that continued to be present at 1 month after birth (Fig. 4B–E). Specifically, at 2-week old, SHP-2IEC-KO mice had a reduction of both bacterial richness (measured as observed species) and diversity (measured with the Shannon’s diversity index) in the cecal microbiota when compared to control mice (Fig. 4F). We observed an increase in the relative abundance of total Proteobacteria (Fig. 4B) and bacteria belonging to the genus Bacteroides and Escherichia in SHP-2IEC-KO in comparison to control mice (all corrected \( P < 0.05 \)) (Fig. 4H). However, SHP-2IEC-KO mice had lower relative abundance of unclassified
Lachnospiraceae and bacteria of the genus Oscillospora, both belonging to the order Clostridiales, than control mice (all corrected \( P < 0.05 \)) (Fig. 4H). Similarly, we observed a reduction in bacterial richness and diversity in the cecal microbiota in 1-month-old SHP-2EC-KO mice when compared to control mice (Fig. 4G). Moreover, SHP-2EC-KO mice had higher relative abundance of total Proteobacteria and lower relative abundance of total Firmicutes when compared to control mice (all corrected \( P < 0.05 \)) (Fig. 4C). In particular, SHP-2EC-KO mice had higher relative abundance of Bacteroidetes and Escherichia genera, but lower of unclassified Lachnospiraceae (all corrected \( P < 0.05 \)) (Fig. 4H). We then targeted changes in specific groups using qPCR, confirming the increases in Enterobacteriaceae and reductions in Firmicutes (Clostridium leptum and Clostridium cocoides) between controls and SHP-2EC-KO mice (Table II). Thus, microbiota alterations in this model occur prior the appearance of clinical signs of colitis and thus it is possible that the dysbiosis contributes to the observed early cell fate alterations that precede inflammation in SHP-2EC-KO mice.

**Epithelial Myd88 deletion inhibits colitis development in SHP-2-deficient mice**

One might speculate that different bacterial microbiota composition and diminished functionality of mucus barrier observed early in SHP-2-deficient mice cause the onset of inflammation. Indeed, we previously demonstrated that treatment of SHP-2EC-KO mice with antibiotics inhibited colitis development (Coulombe et al., 2013). Stimulation of IEC Toll-like receptors (TLR) by luminal commensals provides cytoprotective signals to the host (Rakoff-Nahoum et al., 2004). However, mice with defective immune regulation do not develop colitis in germ-free conditions indicating that commensal bacteria can trigger inflammation (Nell et al., 2010). To, therefore, investigate the role of TLR activation, we crossed SHP-2EC-KO mice with mice lacking epithelial Myd88, an adaptor protein required for signaling by the majority of TLRs (Warner and Nunez, 2013). Of importance, epithelial Myd88 deletion impaired the development of colitis in 1-month-old SHP-2EC-KO mice, as illustrated by the partial restoration of body weight (Fig. 5A), the marked DAI reduction (Fig. 5B), the maintenance of histological integrity (Fig. 5C and D) as well as RelA (p65 regulatory subunit of NFκB) phosphorylation (Fig. 5E). This suggests that TLR-mediated bacterial recognition is involved in colitis initiation in SHP-2EC-KO mice. Importantly, epithelial deficiency of Myd88 alone did not significantly alter Goblet cell number in mice aged of 2 weeks. In addition, no lysozyme-positive cell was detected in the colon of these mice. However, epithelial Myd88 deletion in SHP-2EC-KO mice significantly increased Goblet cell number (Fig. 6A and B) and markedly reduced the number of intermediate cells (lysozyme-positive cells) in comparison to SHP-2EC-KO mice (Fig. 6C). Thus, TLR-Myd88 signaling contributes to the observed early cell fate alterations that precede inflammation in SHP-2EC-KO mice.

**Discussion**

Mice with a deletion of SHP-2 expression specifically in intestinal epithelium spontaneously develop colonic inflammation which resembles to UC (Coulombe et al., 2013; Heuberger et al., 2014; Yamashita et al., 2014). Herein, we observed that one of the earliest physiological modifications observed upon epithelial deletion of SHP-2 in the intestine was the increased expression of many antimicrobial peptides in the colon. Indeed, our results showed that Reg3β, Defx and Lyz1 were markedly induced in the colon of neonate mutants. The induction of Defx and Lyz1 in the colon of mutant mice was surprising as these peptides are mainly produced by Paneth cells that are normally confined at the bottom of the crypts in the small intestine and not in the colon. However, Paneth cell metaplasia has been frequently observed in various sites of inflammation, including the colon (Hiemstra and Zaat, 2013). This metaplastic response is usually viewed as a process which provides additional antimicrobial protection at sites of inflammation (Shi, 2007; Hiemstra and Zaat, 2013). However, herein, expression of Paneth cell genes was detected in newborn mutants and therefore, well before the onset of inflammation detected 1 month after birth. We have also noticed a distinct lysozyme-positive cell population in the colon of our mutant mice. Intriguingly, these lysozyme-positive cells were only detected 2 weeks after birth. These observations are reminiscent of changes that occur during the development and maturation of small intestine after birth. Indeed, in newborn mice, some Paneth cell products including defensins and UEA1 lectin are expressed by epithelial cells of the immature small intestine, well before crypt morphogenesis and formation of Paneth cells (Falk et al., 1994; Darmoul et al., 1997). For instance, mRNA and protein expression of some defensins was detected in P1 mouse intestine, despite the absence of recognizable Paneth cells (Darmoul et al., 1997). Hence, one might speculate that a similar phenomenon occurs in the colon of SHP-2EC-KO neonates. Importantly, these distinct cells were also positive for Alcian blue staining indicating an intermediate phenotype between Paneth and Goblet cells. Such intermediate cells were previously described in the small intestine and presumably represent the common progenitors of the Paneth and Goblet cell lineages (Kamal et al., 2001). Indeed, these particular cells were stained positively for both lysozyme and Alcian blue. Of note, expansion of these

---

**TABLE II. Microbiota composition in SHP-2EC-KO mice compared to control littermates (n ≥ 5 mice per group)**

| Target bacterial group | 2 weeks | 4 weeks |
|------------------------|---------|---------|
|                        | Mean (Ct) | Standard deviation | P-value | Mean (Ct) | Standard deviation | P-value |
| Total bacteria         | Control | 15.32 | 1.65 | 0.132 | 13.09 | 0.97 | 0.257 |
| SHP-2EC-KO             | SHP-2EC-KO | 16.57 | 1.64 | 0.063 | 15.04 | 2.27 | 0.063 |
| Lactobacillus          | Control | 21.22 | 1.68 | 0.762 | 15.85 | 2.32 | 0.999 |
| SHP-2EC-KO             | SHP-2EC-KO | 23.70 | 1.80 | 0.65 | 18.75 | 5.99 | 0.006 |
| Bacteroides fragilis   | Control | 20.70 | 3.26 | 0.24 | 16.18 | 5.56 | 0.012 |
| SHP-2EC-KO             | SHP-2EC-KO | 23.01 | 7.46 | 0.121 | 19.72 | 2.83 | 0.006 |
| Clostridium leptum     | Control | 17.41 | 1.98 | 0.67 | 13.09 | 0.60 | 0.006 |
| SHP-2EC-KO             | SHP-2EC-KO | 20.73 | 2.82 | 0.47 | 18.67 | 4.00 | 0.12 |
| Clostridium cocoides   | Control | 16.80 | 1.84 | 0.24 | 29.02 | 2.64 | 0.012 |
| SHP-2EC-KO             | SHP-2EC-KO | 21.57 | 5.54 | 0.029 | 20.84 | 4.19 | 0.006 |
| Enterobacteriaceae     | Control | 22.85 | 3.47 | 0.006 | 18.21 | 1.79 | 0.006 |
| SHP-2EC-KO             | SHP-2EC-KO | 16.09 | 1.79 | 0.006 | 15.04 | 2.27 | 0.063 |

JOURNAL OF CELLULAR PHYSIOLOGY
intermediate cells in the colon of mutant mice was associated with a marked decrease in the number of mature Goblet cells. Thus, these observations suggest that SHP-2-dependent signaling directs cells to the Goblet cell fate and prevents Paneth cell expansion in the colon. Dysregulation of epithelial cell fate or differentiation in the colon may have serious consequences for the host as exemplified with mice deficient for Muc2 that rapidly develop severe colitis (Van der Sluis et al., 2006).

Notably, antimicrobial peptides have been involved not only in establishing the barrier between microbes and the epithelial cells but also in shaping microbiota composition (Salzman et al., 2010). For example, Paneth cell α-defensins directly regulate microbiota composition as previously demonstrated with mice deficient in Mmp7 (which lack mature α-defensins) and mice expressing human HD5 (which exhibit more α-defensins). Indeed, the lack of mature α-defensins shifts the dominant bacterial phyla present in the small intestine, decreasing the relative abundance of Bacteroidetes, and increasing the relative abundance of Firmicutes. Also, expression of the human defensin HD5 in murine Paneth cells increases the relative abundance of Bacteroidetes, in particular of Bacteroides genus, and decreases Firmicutes (Salzman et al., 2010). These changes in microbiota composition were observed without changes in...
microbial loads suggesting that Paneth cell α-defensins are not involved in regulating the total number of bacteria in the intestine. Of note, at 4 weeks of age, SHP-2 mutant mice had decreased Firmicutes (uncLachnospiraceae and the genus Oscillospira), while Proteobacteria (Escherichia genus) and Bacteroidetes (Bacteroides genus) were increased. Similar changes in microbial composition were observed at 2 weeks, but no significant differences were observed among neonates, suggesting that the diversification of the microbiota occurs postnatally in SHP-2IEC-KO mice. It is of interest that the changes in microbiota observed in SHP-2IEC-KO mice are reminiscent of those reported in IBD patients (Lupp et al., 2007; Kostic et al., 2014). Thus, the results suggest that changes in the expression of a single epithelial phosphatase can have a significant effect on key gut microbial groups important for homeostasis. Interestingly, microbiota alterations in the model occur prior to the appearance of clinical signs of colitis and thus it is possible that they play a role in colitis development.

Several studies indicate that the gut microbiota is required for triggering inflammation and IBD pathogenesis; indeed, short-term treatment with antibiotics dramatically reduces inflammation and exhibits some efficacy in IBD (Casellas et al., 1998). Furthermore, various mouse models failed to develop intestinal inflammation in germ-free setting. Likewise, we previously demonstrated that antibiotic treatment prevented colitis development in SHP-2IEC-KO mice (Coulombe et al., 2013). Additionally, herein we observed that deletion of epithelial Myd88 attenuated colitis severity in this model. Therefore, TLR/Myd88-mediated bacterial recognition by the epithelium may be critical in inducing intestinal inflammation in SHP-2IEC-KO mice. By contrast, a protective function of Myd88 signaling in intestinal epithelium was previously reported (Rakoff-Nahoum et al., 2004). For instance, deletion of Myd88 specifically in IECs triggers spontaneous intestinal inflammation (Gong et al., 2010). This concept is also supported by the severe colitis rapidly observed in mice with IEC-specific deletion of NEMO/IκKγ, a downstream effector of TLRs and Myd88 (Nenci et al., 2007). Interestingly, in these models, diminished expression of antimicrobial peptides and translocation of commensals into the intestinal mucosa were associated with chronic inflammation (Gong et al., 2010; Frantz et al., 2012). Although these studies indicate that epithelial Myd88 signaling mediates mucosal protective functions, we cannot exclude that overactivation of epithelial Myd88 signaling may also induce inflammation. In line with this, previous studies demonstrated that TLR4 deficiency impairs mucosal healing resulting in bacterial translocation (Fukata et al., 2007) while too much TLR4 signaling in the intestinal epithelium (as in villin-TLR4 mice) induces inflammation and tumorigenesis (Fukata et al., 2011). Such dual signaling function has been also observed for NFκB and STAT3 which can drive or attenuate inflammation depending on the specific challenges and pathophysiological conditions (Pasparakis, 2009; Hruz et al., 2010).

In summary, our studies shed new light on the cellular roles of SHP-2 in the colon epithelium, which regulates secretory cell fate, crucial for the maintenance of mucosal barrier function and for the control of host defense. How SHP-2 exactly impacts on cell fate is not totally clear but may rely on its ability to activate the MAP Kinase pathway. Indeed, Heuberger et al. recently reported in the small intestine that SHP-2-dependent...
ERK signaling controls the choice between Goblet and Paneth cell fate. In fact, they have shown that inhibition of ERK signaling in small intestinal organoids and cultured cells promoted Wnt/β-catenin transcriptional activity through the control of relative abundance of Tcf4 isofoms (Heuberger et al., 2014). Although we observed that such cell fate regulation by SHP-2 also occurs in the colon, our data suggest that the molecular mechanisms involved are more complicated and may implicate the contribution of microbiota since epiphielial Myd88 deletion rescued Goblet/intermediate cell ratio and inhibits colitis induction. Future studies are needed to specify which TLRs and Myd88 downstream signaling effectors are involved in cell fate regulation and colitis development in SHP-2−/−EC-KO mice. Interestingly, Myd88 expressed in Paneth cells has been demonstrated to promote the expression of a complex antimicrobial program in the small intestine (Vaishnava et al., 2008). Furthermore, IEC-specific TLR4 deletion markedly increased Goblet cell number in the small intestine (Sodhi et al., 2012). Hence, one might speculate that TLR4/Myd88 signaling increases Myd88 expression in Paneth cells, which can trigger innate immune responses and inflammation in the intestine (Rosenstiel, 2013; Elia et al., 2015; Yu and Gao, 2015). Interestingly, TLR2, TLR4, and TLR5 have been reported to be phosphorylated on tyrosine after stimulation (Arbibe et al., 2000; Sarkar et al., 2003; Isonen et al., 2007; Medvedev et al., 2007); in some cases, this phosphorylation is required for full activation of the downstream signaling. On the other hand, Myd88 protein can also undergo tyrosine phosphorylation after stimulation. However, tyrosine phosphorylation of Myd88 promotes its degradation leading to downregulated TLR signaling (Mansell et al., 2006; Han et al., 2010). Thus, it is possible that SHP-2 regulates TLR/Myd88 signaling in IECs through tyrosine dephosphorylation. Of note, SHP-2 generally phosphorylates tyrosines surrounded by two or more acidic amino acids on the C-terminal side and one or more acidic amino acids on the N-terminal side. SHP-2 also prefers the acidic residue aspartic acid (D) at pY – 2 position with no basic residue on the C-terminal side (Ren et al., 2011; Bunda et al., 2015). We did not find such general SHP-2 recognition consensus motif on Myd88, TLR2, TLR4, TLR5, and TLR9 mouse sequences. Nevertheless, additional experiments such as immunoprecipitations with anti-phosphotyrosine antibodies are needed to firmly determine if phosphorylation of Myd88 and/or certain TLR(s) is increased in SHP-2−/− deficient IECs.

In conclusion, our results suggest that SHP-2 maintains barrier function in the colon and thereby, helps to prevent spontaneous microbeota driven inflammation as seen in patients with IBD (Swidsinski et al., 2005; Fava and Danese, 2011). Hence, our study highlights SHP-2 as a potential new target for therapeutic interventions aimed at improving barrier function in IBD patients.

Acknowledgments

We thank Anne Vézina for technical assistance and Sébastien A. Roy for fruitful discussions. We thank the Electron Microscopy & Histology Research Core of the FMSS at the Université de Sherbrooke for histology, electron microscopy, and phenotyping services. This research was supported by grant from Crohn and Colitis Canada Foundation and Canadian Institutes of Health Research to NR. Geneviève Coulombe is a NSERC Alexander Graham Bell student scholar. Ariane Langlois was supported by the 2014 Crohn’s and Colitis Canada Summer Stundenship award. Nathalie Rivard, François Boudreau, and Nathalie Perreault are members of the FRSQ-Funded Centre de Recherche du CHUS. Nathalie Rivard is a recipient of a Canada Research Chair in colorectal cancer and inflammamatory cell signaling. Elena F. Verdú holds a CRC and is funded by a Crohn’s and Colitis Canada grant. Giada De Palma holds a PDF by CIHR/ CAG, and just Martinnevill a Canadian Celiac Association student award.

Literature Cited

Arbibe L, Mina JP, Teusch N, Klies L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ, Kraus UG. 2000. Toll-like receptor 2-mediated NF-κappa B activation requires a PDI-dependent pathway. Nat Immunol 1:533–540.

Bevins CL, Salaman NH. 2011. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 9:356–368.

Boudreau F, Lusser CR, Morgain S, Darismy G, Drouin JL, Doyon G, Suh ER, Beaulieu JF, Rivard N. Perreault N. 2007. Loss of Myd88 results in overexpression and intestinal neoplasia. FASEB J 21:3853–3865.

Bunda S, Burrell K, Heir P, Zeng L, Alasmashhepov A, Kano Y, Raubitschek A, Zhang ZY, Zadeh G, Ohls AL. 2015. Inhibition of phosphorylation of Ras suppresses oncogenesis. Nat Commun 6:6859.

Calvert R, Bordeleau G, Grondon G, Vezina A, Ferrari J. 1988. On the presence of intermediate cells in the small intestine. Anatom Rec 220:291–295.

Caporaso GJ, Kuczynski J, Stombaugh J, Bittinger K, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Knight TS, Koenig JE, Ley RE, Logan M, McDonald D, McGinnis W, Mehta K, Muehlner M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann T, Yatsunenko T, Zaneveld J, Knight R, Birren S. 2010. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7:335–336.

Casetti F, Antolini M, Videla V, Malagolada JR. 1998. Antiinflammatory effects of enterically coated amoxicillin-clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis 4:1–5.

Cho JH, Brant SR. 2011. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 140:1704–1712.

Cooper HS, Murthy SN, Shah RS, Sedergran DJ. 1993. Pathologic pathogenesis of dextran sodium sulfate induced colitis in mice. Lab Invest 69:238–249.

Coskun M. 2014. Intestinal epithelium in inflammatory bowel disease. Front Med 1:24.

Coulombe G, Leblanc C, Cagnol S, Maloum F, Lemieux E, Perreault N, Feng GS, Boudreau F, Rivard N. 2013. Epithelial tyrosine phosphorylation of Myd88 protects against intestinal inflammation in mice. Mol Cell Biol 33:2275–2284.

Dharm D, Brown D, Selsted ME, Ouellette AJ. 1999. Cryptin gene expression in bone marrow mouse small intestine. J Cell Physiol 179:512–520.

Elia PP, Tolentino YF, Bernardacci C, de Souza HS. 2015. The role of innate immunity receptors in the pathogenesis of inflammatory bowel disease. Mediators Inflamm 2015:5264193.

Falk P, Roda KA, Gordon JN. 1994. Lectins are sensitive tools for defining tissue specific mouse gut epithelial cell lineages. Ann N Y Acad Sci 666:907–1003.

Fava F, Danese S. 2011. Intestinal microbiota in inflammatory bowel disease: Friend or foe? World J Gastroenterol 17:557–566.

Feng J, Rogier EW, Reem G, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Cooper HS, Elson G, Kosco-Vilbois M, Zaias J, Perez MT, Mayer L, Vamadevan AS, Lira SA, Coufoulis G, Leblanc C, Cagnol S, Maloum F, Lemieux E, Perreault N, Feng GS, Boudreau F, Rivard N. 2013. Epithelial tyrosine phosphorylation of Myd88 regulates TLR/Myd88 signaling in IECs through tyrosine dephosphorylation. Of note, SHP-2 generally phosphorylates tyrosines surrounded by two or more acidic amino acids on the N-terminal side and one or more acidic amino acids on the C-terminal side. SHP-2 also prefers the acidic residue aspartic acid (D) at pY – 2 position with no basic residue on the C-terminal side (Ren et al., 2011; Bunda et al., 2015). We did not find such general SHP-2 recognition consensus motif on Myd88, TLR2, TLR4, TLR5, and TLR9 mouse sequences. Nevertheless, additional experiments such as immunoprecipitations with anti-phosphotyrosine antibodies are needed to firmly determine if phosphorylation of Myd88 and/or certain TLR(s) is increased in SHP-2−/− deficient IECs.

In conclusion, our results suggest that SHP-2 maintains barrier function in the colon and thereby, helps to prevent spontaneous microbiota driven inflammation as seen in patients with IBD (Swidsinski et al., 2005; Fava and Danese, 2011). Hence, our study highlights SHP-2 as a potential new target for therapeutic interventions aimed at improving barrier function in IBD patients.

Acknowledgments

We thank Anne Vézina for technical assistance and Sébastien A. Roy for fruitful discussions. We thank the Electron Microscopy & Histology Research Core of the FMSS at the Université de Sherbrooke for histology, electron microscopy, and phenotyping services. This research was supported by grant from Crohn and Colitis Canada Foundation and Canadian Institutes of Health Research to NR. Geneviève Coulombe is a NSERC Alexander Graham Bell student scholar. Ariane Langlois was supported by the 2014 Crohn’s and Colitis Canada Summer Stundenship award. Nathalie Rivard, François Boudreau, and Nathalie Perreault are members of the FRSQ-Funded Centre de Recherche du CHUS. Nathalie Rivard is a recipient of a Canada Research Chair in colorectal cancer and inflammamitory cell signaling. Elena F. Verdú holds a CRC and is funded by a Crohn’s and Colitis Canada grant. Giada De Palma holds a PDF by CIHR/ CAG, and just Martinnevill a Canadian Celiac Association student award.
Lupp C, Robertson ML, Wickmat ME, Sekirov I, Champion OL, Goynor EC, Floren BB. 2007. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2:204.

Madison BB, Dunder L, Qiao XT, Braunstein K, Braunstein E, Gumucio DL. 2002. cis elements of the villin gene control expression in restricted areas of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem 277:33275–33283.

Malinen E, Kassenin A, Rinttila T, Palva A. 2003. Comparison of real-time PCR with SYBR Green I or 3′-nuclease assays and dot-blot hybridization with rDNA-targeted oligonucleotide probes in quantification of selected fecal bacteria. Microbiology 149:269–277.

Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, Crack PJ, Nicholson SE, Hilton DJ, O’Neill LA, Hertzog P. 2006. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Paf1 degradation. Nat Immunol 7:148–155.

Martin M. 2011. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17:10–12.

Masella AF, Bartram AK, Truskowski JM, Brown DG, Neufeld JD. 2012. PANDAseq: Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Matsuki T, Watanabe K, Fujimoto J, Miyamoto Y, Takada T, Matsumoto K, Oyaizu H, Tanaka R. 2002. Development of 16S rDNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces. Appl Environ Microbiol 68:5445–5451.

McCaffery DM, Miamampaha M, Sihota E, Sharkey KA, Kubes P. 1999. Role of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced colitis in mice. Gut 45:864–873.

McMurdie PJ, Holmes S. 2013. Phyloseq: An R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 8:e61217.

Medvedev AE, Piao W, Shoenfelt J, Rhee SH, Chen H, Baus S, Wahl LM, Fenton MJ, Vogel SN. 2007. Role of TLR4 translocation in signal transduction and endotoxin tolerance. J Biol Chem 282:16402–16405.

Narumi Y, Isomoto H, Shiota M, Sato K, Oka M, Majima K, Ota H, Kohno S, Tsukamoto K. 2009. Polymorphisms of PTPN11 coding SHP-2 as biomarkers for ulcerative colitis susceptibility in the Japanese population. J Clin Immunol 29:303–310.

Neill S, Suerbaum S, Josepshans C. 2010. The impact of the microbiota on the pathogenesis of IBD: Lessons from mouse infection models. Nat Rev Microbiol 8:564–573.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.

Paired-end assembler for illumina sequences. BMC Bioinformatics 13:31.